Cyprus Mail on MSN
Travere wins FSGS approval for FILSPARI, a milestone for holders including Armistice Capital
Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results